<scp>BDA</scp> ‐410 inhibits <scp>SARS‐CoV</scp> ‐2 main protease activity and viral replication in mammalian cells-Reference-Cited by-同舟云学术

BDA ‐410 inhibits SARS‐CoV ‐2 main protease activity and viral replication in mammalian cells

Published:2022-09-09 Issue:19 Volume:26 Page:5095-5098
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cellular Molecular Medi

Author:

Schwake Christopher¹,McKay Lindsay²,Griffiths Anthony²,Scartelli Christina³,Flaumenhaft Robert³,Chishti Athar H.¹^ORCID

Affiliation:

1. Department of Developmental, Molecular, and Chemical Biology, Graduate School of Biomedical Sciences Tufts University School of Medicine Boston Massachusetts USA

2. National Emerging Infectious Diseases Laboratories (NEIDL), Department of Microbiology Boston University Boston Massachusetts USA

3. Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center Harvard Medical School Boston Massachusetts USA

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.17442

Reference17 articles.

1. Identification of Severe Acute Respiratory Syndrome Coronavirus Replicase Products and Characterization of Papain-Like Protease Activity

2. Papain-Like Protease 2 (PLP2) from Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV): Expression, Purification, Characterization, and Inhibition

3. Severe Acute Respiratory Syndrome Coronavirus Papain-like Novel Protease Inhibitors: Design, Synthesis, Protein−Ligand X-ray Structure and Biological Evaluation

4. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

5. A comprehensive review on promising anti-viral therapeutic candidates identified against main protease from SARS-CoV-2 through various computational methods